Introduction: Osimertinib is standard treatment for patients with advanced EGFR T790M-mutated non-small-cell lung cancer who have been pre-treated with EGFR-tyrosine kinase inhibitors (TKIs). We studied whether cell-free plasma DNA for T790M detection can be used to select patients for osimertinib treatment in the clinical routine.
Introduction
Patients with advanced epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC) receive first-or second-generation EGFR tyrosinekinase inhibitors (TKIs). Treatment is associated with response rates of 56% to 74% and a median progressionfree survival (PFS) of approximately 12 months. [1] [2] [3] [4] [5] [6] [7] However, the majority of patients will acquire resistance to EGFR-TKIs and progress. This acquired resistance is caused by the EGFR p.Thr790Met point mutation (T790M) in approximately 50% to 70% of these patients. [8] [9] [10] [11] [12] This mutation leads to an enhanced affinity of the EGFR kinase domain for adenosine triphosphate, thereby reducing the ability of adenosine triphosphate -competitive reversible EGFR-TKIs to bind to the tyrosine-kinase domain of EGFR. Irreversible third-generation EGFR-TKIs such as osimertinib may overcome this mechanism of resistance. 13, 14 Osimertinib inhibits activating mutations and the T790M mutation, while sparing wild-type EGFR. 15 Previous clinical trials showed that third-generation TKIs are highly active in patients with advanced T790M-mutated NSCLC who had progressed during treatment with first-or second-generation EGFR-TKIs. 13, 14, 16, 17 The AURA3 phase III trial showed that osimertinib prolonged PFS compared to platinum-based chemotherapy and was associated with higher response rates in advanced T790M-mutated NSCLC patients who had progressed under treatment with first-or second-generation EGFRTKIs. 17 Based on this study, osimertinib has been established as standard treatment for T790M-positive patients.
The clinical use of osimertinib in patients with advanced NSCLC requires proof of the presence of the T790M mutation in tumor cells. Tumor re-biopsy remains challenging in routine practice because of poor performance status of many patients, potential inaccessibility of the tumor, and occasional insufficient tumor material for genetic analyses. Therefore, minimally invasive techniques such as analysis of cell-free plasma DNA from blood samples (liquid biopsy) may be preferable alternatives in these patients. [18] [19] [20] Several studies have now suggested that highly sensitive genotyping assays, for example, droplet digital polymerase chain reaction (ddPCR) or beads, emulsions, amplification, and magnetics (BEAM)ing digital polymerase chain reaction (PCR), can indeed detect mutations in cell-free plasma DNA. 12, [21] [22] [23] [24] These tests also allow quantitative analysis. However, the clinical relevance of low-prevalence mutant alleles is unknown.
The aims of our study were the following: (1) to use liquid biopsy specimens supported by tissue analyses to detect the T790M mutation; (2) to study the outcomes of patients with T790M-positive tumors and compare them with AURA3 results; and (3) to determine whether quantitative analysis of T790M may be of further value. Here we report the results of our study.
Patients and Methods

Patients
Patients with advanced EGFR-mutated NSCLC who had progressed during at least one first-or secondgeneration EGFR-TKI were recruited at nine participating centers in Austria between April 2015 and November 2016. All patients had a confirmed activating EGFR mutation in the initial biopsy at diagnosis and were required to provide a blood sample to test for T790M in cell-free plasma DNA. A new tumor biopsy (re-biopsy) for tissue genotyping was obtained at the time of disease progression according to institutional practice. Among patients who clinically progressed during EGFR-TKI treatment, plasma analyses was performed for all patients and, independent of the results of plasma analyses, tumor analyses was performed only for those patients in whom biopsy was clinically feasible as judged by the treating physician. The detection and monitoring of somatic EGFR-activating and drug resistance mutations in cell-free plasma DNA was performed at the Department of Medicine I, Medical University of Vienna. T790M-positive patients received oral osimertinib at a dose of 80 mg once daily until disease-progression and/ or unacceptable toxicity. Patients received osimertinib initially as part of an Exceptional Access Program and after osimertinib approval as part of their routine treatment. T790M-negative patients were planned for chemotherapy.
The study protocol as well as the consent form were approved by the local ethics committee (EK Nr: 1132/ 2016) and all patients gave their written informed consent for providing a blood specimen for plasma genotyping and/or a tumor biopsy for tissue genotyping.
Blood Collection
Blood samples (8 mL each) were either collected in ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes or in Cell-Free DNA blood collection tubes (BCTs) (Streck, La Vista, NE). Collection in EDTAcontaining vacutainer tubes required further plasma preparation within 2 hours. In Cell-Free DNA BCTs no immediate processing of plasma was required as cellfree DNA could be stabilized for several days. Blood samples were centrifuged at 200 g for 10 minutes and subsequently at 1600 g for 10 minutes to separate the plasma from the peripheral blood cells. Plasma supernatant was then again centrifuged for 1900 g for 10 minutes and stored in 1 mL aliquots at -80 C until DNA extraction.
ddPCR
The plasma analyses were performed by A. B. at the Department of Medicine I, Medical University of Vienna, in an International Organization for Standardizationcertified research lab in close cooperation with the respective pathology departments of the participating centers.
Cell-free plasma DNA was extracted from 2 mL of plasma using the QIAamp circulating nucleic acid kit (Qiagen, Venlo, Netherlands) according to the manufacturer's instructions.
The EGFR-activating mutations exon 19 deletions and L858R as well as the T790M and C797S resistance mutations were assessed by using the QX-100 ddPCR system (Bio-Rad, Hercules, CA). Primer/probe mixes for EGFR exon 19 deletions, L858R, T790M, and C797S mutations were custom-made by Life Technologies (Carlsbad, CA). Primer and probes were used as previously described. 22 C and a hold at 10 C. DNA samples were mixed with 20x TaqMan primer/probes and 2x ddPCR Supermix (Bio-Rad) to a final volume of 22 mL. Twenty microliters of this ddPCR reaction mixture were loaded into the DG8 droplet generator cartridge (Bio-Rad), and the cartridge was then placed into the QX100 droplet generator. Generated droplets were transferred from the cartridge to a 96-well PCR plate and PCR was performed to end point by using a conventional thermal cycler. After PCR, the 96-well PCR plate was placed in the QX-100 droplet reader (Bio-Rad) for the detection of positive and negative droplets by a 2-color detector. Analysis of ddPCR data was performed by using QuantaSoft analysis software (Bio-Rad). Results were reported as copies of mutant allele per milliliter of plasma. All ddPCR assays were analyzed in triplicate and results were reported as copies of mutant allele per milliliter of plasma as previously described. 22, 23 Thresholds for positivity were >5 copies/mL for EGFR exon 19 deletions, >2 copies/mL for L858R, and >1 copy/mL for T790M. 23 We used cell lines and selected plasma specimens to validate these thresholds in our laboratory before using them to study patient specimens.
Statistical Analyses
The primary endpoint was PFS as determined by investigator assessment. Overall survival (OS), response rate (RR), and disease control rate (DCR) were secondary endpoints. Tumor response was assessed by a contrast enhanced computed tomography of the chest and abdomen by the local radiologist according to institutional practice. The scan intervals were usually between 6 to 8 weeks at the treating physician's discretion. In addition, response was confirmed post hoc using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by an expert radiologist (H. P.). RR was defined as the percentage of patients with response (complete or partial) at restaging after osimertinib initiation. The DCR was the percentage of patients who had a complete response, a partial response, or stable disease lasting for 6 weeks or longer before diseaseprogression.
OS was defined as the time from first osimertinib dose to death from any cause and PFS as the time from first osimertinib dose to disease progression or death from any cause, whichever came first.
Patient and tumor characteristics included age, sex, presence or absence of extrathoracic metastases, tissue genotype at diagnosis, and previous EGFR-TKI therapy. Associations of plasma genotyping results (copies per milliliter of plasma) with clinical parameters including treatment response were assessed by the chi-square test. Survival probabilities were calculated with the product limit method according to Kaplan-Meier. All reported p values are two-sided. All analyses were performed using IBM SPSS Statistics software, version 23 (SPSS, IBM Corporation, Armonk, NY).
Results
At the time of disease progression to first-or secondgeneration EGFR-TKI therapy, plasma samples of 119 patients were centrally analyzed by ddPCR for EGFR exon 19 deletions, L858R, and the T790M mutation. Forty-nine of 119 (41%) patients had an additional tissue re-biopsy and were evaluated for EGFR-sensitizing mutations and the T790M mutation. A study flowchart is shown in Figure 1 . The T790M resistance mutation was detected in plasma in 85 (71%) patients and was not detectable in 30 (25%) patients. One-fourth of patients without cell-free DNA in the plasma (no wild-type or mutant EGFR detectable) was T790M positive in the tissue. Five of eight plasma-negative patients were T790M positive by tissue analyses. Two T790M-mutated patients who died before the first cycle of osimertinib due to rapid disease progression were included in the intention-to-treat analyses. Thus, a total of 91 T790M-positive patients were enrolled in the osimertinib intention-to-treat population (Fig. 1) .
The characteristics of the osimertinib study population are summarized in Table 1 . All patients had adenocarcinoma histology and stage IV disease. Twelve percent of the patients had thoracic metastases and 88% had extrathoracic metastases. The tissue genotype which had been evaluated at the time of initial diagnosis included EGFR exon 19 deletions in 55 (60%) patients, L858R in 28 (31%), and rare EGFR mutations in 8 (8%) patients. All patients were pretreated with EGFR-TKIs -38 (42%) received gefitinib, 7 (8%) erlotinib, 29 (32%) afatinib, and 17 (19%) were treated with more than one TKI. Median time from initial diagnosis of NSCLC until start of osimertinib therapy was 25 months (range, 3 to 62 months).
T790M was detected by analyses of cell-free plasma DNA in 85 of 91 (93%) patients and in 6 (7%) plasmanegative patients by tumor re-biopsy. T790M-positivity in plasma ranged from 1.6 to 38,092 copies/mL. The median T790M mutant allele copy number per milliliter was 10. In plasma, EGFR exon 19 deletions were positive in 38 of 55 (69%), and L858R in 22 of 28 (79%) patients, respectively. We also analyzed the allelic frequency of T790M as compared to the original EGFR-sensitizing mutations. The T790M mutation was detected in the plasma of 17 of 51 (33%) patients with EGFR exon 19 deletions and of 5 of 27 (19%) patients with the L858R mutation. The median ratio between T790M and the EGFR-sensitizing mutation was 0.28 (range, 0.007 to 5.2) and was not significantly associated with response (median ratio 0. 33 Figs. 1  and 2 ). Among the 34 patients with T790M-positive tumor tissue, 28 also had T790M-positive plasma (82% sensitivity). Re-biopsy was performed in 8 of 30 (27%) T790M plasma-negative patients and in 40 of 85 (47%) T790M plasma-positive patients. The tissue biopsy was not evaluable due to insufficient amount of tumor cells in four patients. Patients with T790M-negative cell-free plasma DNA but T790M-positive tissue biopsy were also enrolled (Fig. 1) .
The clinical characteristics of osimertinib-treated patients according to T790M mutation copy number in cellfree plasma DNA is shown in Table 2 . We observed no significant association between T790M mutation copy number and age, sex, presence or absence of extrathoracic metastases, tissue genotype at diagnosis, previous EGFR-TKI therapy, as well as re-biopsy (Table 2) .
Next, we determined the outcome of the osimertinib intention-to-treat population (n ¼ 91). Median PFS was 10.1 months (95% CI: 8.1-12.1 months) (Fig. 3A) (Fig. 3E) .
As shown in Figure 3B median survival was not reached and the 1-year survival rate was 64%. OS was not associated with age (p ¼ 0.68), sex (p ¼ 0.09), or previous EGFR-TKI therapy (p ¼ 0.57). However, OS was significantly associated with tissue genotype at diagnosis (HR ¼ 2.65, 95% CI: 1.54-4.54, p < 0.001). Patients with EGFR exon 19 deletions had longer OS (median not reached) than those with L858R (median, 10.4 months) and those with other EGFR mutations (median, 1.4 months) (Fig. 3D) . No difference in OS was observed between patients with EGFR exon 19 deletions and those with the L858R mutation (HR ¼ 0.73, 95% CI: 0.27-2.00, (Fig. 3F ).
Response to osimertinib was assessed in the intention-to-treat population (n ¼ 91) (Fig. 1) . The RR was 70% (64 of 91 patients) and the DCR was 81% (74 of 91 patients) ( Table 3 ). The RR was 82% and the DCR was 93% in 27 patients who were T790M positive in both plasma and tumor tissue. The RR was significantly associated with the tissue genotype at diagnosis. Patients with EGFR exon 19 deletions had more complete responses than patients with the L858R mutation in their tumors (27% versus 7%, p ¼ 0.04). In the small subset of patients with uncommon EGFR mutations who were evaluable for response (n ¼ 6), the RR was significantly lower compared with patients with EGFR exon 19 deletions or the L858R mutation (33% versus 79%, p ¼ 0.01). The RR was similar between patients with a low T790M copy number and those with a high T790M copy number (79% versus 83%, p ¼ 0.67).
Finally, we monitored cell-free plasma DNA from 41 patients during the course of treatment with osimertinib for presence of EGFR exon 19 deletions, L858R, T790M, and the C797S mutations. In 26 patients who had progressed on osimertinib, the T790M mutation persisted in 11 cases (42%). Three (12%) of these patients who had progressed during osimertinib treatment acquired the C797S mutation. All three cases maintained the T790M mutation and the initial EGFR exon 19 deletion.
Discussion
The AURA 3 phase III trial recently showed greater efficacy for osimertinib compared to platinum therapy plus pemetrexed in patients with centrally confirmed T790M-mutated advanced NSCLC who had progressed during first-line EGFR-TKI therapy (median PFS, 10.1 versus 4.4 months; RR 71% versus 31%) and, therefore, established osimertinib as the new treatment standard for these patients. 17 This now also requires proof of the presence of the T790M mutation in tumor cells by either tissue genotyping as done in the AURA3 trial or plasma genotyping before osimertinib treatment. 17, 19, 26 Our study results suggest that T790M detection based on analyses of cell-free plasma DNA and supported by tissue biopsy in those patients in whom rebiopsy was judged feasible by the treating physician appears to be a strategy to guide treatment with osimertinib in the real-world setting. The majority of our patients (93%) who were selected for osimertinib treatment were T790M positive in plasma analyses. Only 7% of our patients were entered into the trial based on tissue positivity while being negative in plasma analyses. Using this strategy, tissue biopsy would be avoided in more than 70% of the patients. Due to the well-known difficulties of tumor re-biopsy at the time of disease progression in advanced NSCLC, we were able to perform re-biopsy of tumors in only 42% of our patients, which is in a lower reported range and may be explained by the multicenter nature of our study. The re-biopsy rate was even lower in patients with T790M plasmanegative patients compared to T790M plasma-positive patients (27% versus 47%). Whether the lower rebiopsy rate in patients with T790M-negative plasma is caused by lower patient numbers in this group and/or a clinically more aggressive phenotype prohibiting rebiopsy remains unclear.
The fact that the characteristics and the clinical outcomes of our patients were similar to those of the AURA3 trial (Table 4) , in which enrollment was based on a T790M-positive tumor sample, supports the clinical relevance of our strategy which was based on cell-free plasma DNA analysis.
The plasma T790M-positivity of 71% in our study is consistent with results from other reports 27, 28 or the AURA phase I trial in which retrospective analyses of blood samples revealed a T790M-positivity rate of 60% for plasma genotyping by BEAMing compared to 73% with tissue genotyping using the cobas EGFR Mutation Test (Roche Molecular Systems, Inc., Pleasanton, CA).
12
Outcomes from osimertinib treatment in the AURA trial were similar in patients with plasma genotyping (median PFS, 9.7 months, RR: 63%) and those with tissue genotyping (median PFS, 9.7 months, RR: 62%). 12 We observed a similar efficacy with a median PFS of 10.1 months and an RR of 70%. Minimally invasive plasma genotyping represents an attractive alternative for detection of T790M. Our finding that analyses of cell-free plasma DNA can replace tissue analyses in the majority of cases should facilitate management of patients in routine clinical practice. Liquid biopsy specimens may offer additional advantages. Blood samples are easily obtainable and can be obtained repeatedly even in short time intervals. In addition, plasma genotyping may better represent the mutation status across all tumor manifestations in the body compared to a single tissue biopsy which may provide only an incomplete picture of the tumor genome. Furthermore, blood-based analytic approaches may allow real-time monitoring of the total tumor burden and the detection of upcoming mutations that arise during clinical treatment through serial blood sampling and analysis. Several studies have shown that highly sensitive digital genotyping assays such as ddPCR or BEAMing digital PCR can indeed accurately detect mutations in cell-free plasma DNA. 12, [21] [22] [23] 29 These methods are enhancements of conventional PCR with higher sensitivity and specificity and allow absolute quantification of T790M mutations in plasma samples which is particularly important for treatment monitoring. The clinical utility of the cobas EGFR Mutation Test version 2 for T790M detection has been previously shown in cell-free plasma DNA samples obtained from patients who had been enrolled in the AURA extension and AURA2 trials. 30 Comparison of the cobas test with BEAMing digital PCR showed that BEAMing has a higher sensitivity but the cobas test has a higher specificity compared to tissue testing. 31 One limitation of the ddPCR assay is that it detects only one mutation per PCR assay and, therefore, specific PCR assays for each mutation have to be designed. We used the highly sensitive ddPCR to detect the T790M mutation. This is particularly important because 46% of our patients had a T790M copy number below 10 which is below the detection limit of 25 T790M copies/mL of the cobas EGFR Mutation Test version 2. The value of a low T790M copy number has been unknown until now. Our findings suggest that patients with low T790M allele frequency may have prolonged PFS and OS. Based on our single-arm study, however, we cannot determine whether this improved outcome reflects better prognosis and/or better response to osimertinib. However, it has been shown in several studies that a high level of cell-free tumor DNA in plasma is a poor prognostic marker. [32] [33] [34] Recently, the FLAURA randomized phase III trial showed a PFS benefit for osimertinib compared to erlotinib or gefitinib in the first-line treatment of NSCLC patients with EGFR exon 19 deletions or L858R mutations. 35 The median PFS was 18.9 months with osimertinib compared to 10.2 months for erlotinib or gefitinib, with an HR of 0.46 (95% CI: 0.37-0.57, p < 0.0001). In those patients who receive osimertinib as first-line treatment, testing for the T790M resistance mutation may be obsolete. The clinical value of treatment monitoring during therapy with osimertinib and the analysis of acquired resistance mechanisms to osimertinib remains to be determined.
In patients (n ¼ 26) who had progressed on osimertinib, we observed the C797S mutation in three cases (12%). This C797S positivity rate is lower than the previously published 40% (6 of 15 cases).
25 C797S-mediated resistance can be overcome in mouse models by the recently developed drug EAI045 in combination with cetuximab. 36 Additional resistance mechanisms contribute to the failure of osimertinib treatment. Although NRAS mutations have been shown to mediate acquired resistance to osimertinib in cell lines and mouse models, their role in clinical resistance remains to be determined. 37 In conclusion, plasma analyses using ddPCR for T790M detection supported by tumor tissue analyses in plasma-negative cases should be a clinically useful strategy to select EGFR-mutated NSCLC patients for osimertinib treatment. 
